MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. Analysts at four equity research firms boosted their price targets for GE Healthcare since the maker of … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Benchmark gauges notched all-time highs as stocks charged through a busy earnings season. . MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Source
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE As the old Wall Street adage goes, health care tends to underperform the stock market in presidential election years — and in recent cycles, that’s been true. But, there’s reason to believe this year that many health-related stocks, led by Eli Lilly , could defy historical … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Jim Cramer urged Humana (HUM) not to pursue a merger with rival health insurer Cigna (CI), questioning the merits of a potential business combination and the likelihood of it passing U.S. antitrust review. Cigna and Humana could reach an agreement on a stock-and-cash transaction by the … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Amazon (AMZN) said on Wednesday that it’s offering Prime members a discount on its new health-care service — another perk that should help bring more people into the online retailer’s ecosystem. The One Medical service, which typically costs $199 annually, will be available to Prime subscribers … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Elevated bond yields and geopolitical uncertainty continued to be negative for stocks this week as the overall market moved into oversold territory. However, that set us up to put cash to work and make four small buys as our discipline mandates. We also upgraded one of … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Traders work at the post where UnitedHealth Group is traded on the floor of the New York Stock Exchange. Brendan McDermid | Reuters UnitedHealth Group‘s (UNH) quality quarterly results Friday are a good sign for the broader health-care landscape, CNBC’s Jim Cramer said. The managed-care giant … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE It’s encouraging to see three Club stocks on the bullish side of Goldman Sachs’ new list of 25 tactical trades for earnings season. Asset allocation can be strategic or tactical. Strategic asset allocation generally refers to longer-term investing — think of this as your buy-and-hold approach. … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE CNBC’s Jim Cramer on Wednesday praised the incoming CEO of Walgreens Boots Alliance, saying industry veteran Tim Wentworth is the right choice to lead the struggling pharmacy chain in its transition to offering more health-care services. “This guy is the real deal. I just salute him … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to continue in their current fiscal years. Long-term investors should look to own companies with a history of dividend growth instead … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Jim Cramer on Squawk on the Street, June 30, 2022. Virginia Sherwood | CNBC CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid. “The biggest … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE We care much more about where a stock is going than where it’s been. With the spin-off of Veralto (VLTO) complete, we decided to look at the path ahead for Danaher (DHR) — now free of its slower-growing, lower-margin water business. In the separation , we … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Danaher (DHR) is days away from shedding its environmental-and-applied solutions segment, and the Club holding’s ability to deliver returns for shareholders appears stronger than ever. Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that’s in the … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE There’s Eli Lilly (LLY), and then there’s everybody else. That’s a simple way to describe the performance of the Club’s health-care holdings so far this year, in what’s been a challenging period for the industry overall. Of the 11 market sectors year to date, health care … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE The rise of new anti-obesity medications could result in less alcohol consumption, impacting Club name Constellation Brands (STZ). The risk already seems to be playing out in food stocks with exposure to snacks and junk food. However, if necessary, the Mexican beer powerhouse behind Corona, Modelo … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Medical equipment giant Danaher (DHR) will officially spin off its environmental-and-applied solutions segment later this month, and our plan is to remain invested in the soon-to-be standalone company, known as Veralto, which will trade under the ticker symbol VLTO. That expectation was reinforced Wednesday when Veralto … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company’s macular degeneration treatment. If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free. CNBC’s Jim Cramer … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE The extraordinary activist-investor interest in Salesforce (CRM) eased further in the second quarter, according to the latest regulatory filings from influential Wall Street pros. These big-name investors also made moves in nine other Club stocks during a strong three-month stretch that ended the best first half … Read more
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE In a jam-packed week of earnings, the Club executed multiple trades and elevated price targets for some of our biggest stocks. Many of these moves stemmed from what we saw in quarterly numbers and heard on conference calls. Here’s a day-by-day look at the portfolio action. … Read more